Edition:
United Kingdom

scPharmaceuticals Inc (SCPH.OQ)

SCPH.OQ on NASDAQ Stock Exchange Global Market

5.10USD
21 Sep 2018
Change (% chg)

$-0.06 (-1.16%)
Prev Close
$5.16
Open
$5.16
Day's High
$5.16
Day's Low
$5.10
Volume
14,572
Avg. Vol
25,623
52-wk High
$18.17
52-wk Low
$4.15

Summary

Name Age Since Current Position

John Tucker

President, Chief Executive Officer, Director

Troy Ignelzi

42 Chief Financial Officer

Abraham Ceesay

Chief Operating Officer

Minnie Baylor-Henry

2018 Director

Mason Freeman

2018 Director

Biographies

Name Description

John Tucker

Mr. John H. Tucker is President, Chief Executive Officer, Director of the Company, Mr. Tucker served as chief executive officer of Algal Scientific, a developer of auto-immune products. There he repositioned the company and successfully negotiated its sale. Prior to Algal, he served as chief executive officer at Alcresta, a developer of enzyme-based products for patients with acute and chronic diseases. While at Alcresta he led regulatory and financing strategies leading to its first product approval and increased valuation. Prior to Alcresta, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS™, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an MBA from New Hampshire College.

Troy Ignelzi

Mr. Troy A. Ignelzi is Chief Financial Officer of the Company. Troy Ignelzi is a senior financial executive with more than 20 years experience in finance, operations and business development with start-up and established companies. Mr. Ignelzi has raised over $300 million in private/public equity and debt, in-licensed commercial technology and completed extensive investor outreach. Prior to scPharmaceuticals, Troy served as a member of the executive leadership teams at Juventas Therapeutics, Esperion Therapeutics (ESPR) and Insys Therapeutics (INSY) where he successfully led various equity and debt financings to fund pharmaceutical and drug device development from pre-IND through commercialization Troy holds a B.S. Accounting from Ferris State University, MI.

Abraham Ceesay

Mr. Abraham Ceesay is Chief Operating Officer of the Company. Mr. Ceesay brings extensive experience in the launch and growth of innovative therapeutic products and a strong track record in leading global commercial teams and development oriented organizations to commercial stage companies. Prior to joining scPharmaceuticals, Mr. Ceesay served as Vice President, Sales, Marketing, and Commercial Operations at Keryx Biopharmaceuticals where he developed the commercial organization and strategy for the company’s inaugural product Auryxia. Prior to his career at Keryx, Mr. Ceesay spent four years at Ironwood Pharmaceuticals as Vice President, Marketing, where he led the launch of the company’s inaugural product Linzess and held responsibility for the management of the U.S. P&L, leadership of the Linzess brand team and co-promotion collaboration with Forest Laboratories/Allergan. Mr. Ceesay also spent eight years at Genzyme/Sanofi, initially as a field sales specialist and ultimately as the Director, Renal Global Marketing, in which capacity he led the global launch of Renvela and held global marketing responsibility for the company’s renal franchise. Mr. Ceesay holds a bachelor’s degree from Ithaca College, and a Masters of Business Administration from Suffolk University’s Sawyer School of Management.

Minnie Baylor-Henry

Ms. Minnie Baylor-Henry is Director of the Company. Ms. Baylor-Henry has over 20 years regulatory affairs experience and is a recognized leader in strategically handling complex regulatory and policy affairs for companies in the life sciences industry. Currently, Minnie is the President of B-Henry & Associates, a consulting organization focused on providing regulatory and strategic support to life science companies. Prior to her work at B-Henry, Ms. Baylor-Henry held multiple positions at Johnson & Johnson, including as the Worldwide Vice President, Regulatory Affairs-Medical Devices and as Vice President, Medical & Regulatory Affairs of the Specialty Pharmaceuticals and Over-the-Counter Products (McNeil Consumer Health Care Division). Ms. Baylor-Henry also spent nine years in various roles at the U.S. Food & Drug Administration including in regulatory review, drug marketing and communications, and regulatory affairs. Ms. Baylor-Henry holds a B.S. from Howard University and a J.D. from Columbus School of Law.

Mason Freeman

Dr. Mason Freeman, M.D., is Director of the Company. Dr. Freeman is a venture partner at 5AM Ventures, a life sciences focused investment firm, which he joined initially as scientific advisor in 2007. In addition to his work at 5AM Ventures, Dr. Freeman serves as Chief of the Lipid Metabolism Unit and director of translational medicine at Massachusetts General Hospital and is a professor at Harvard Medical School. Dr. Freeman currently serves on the Board of Directors of Crinetics Pharmaceuticals, a public company developing therapeutics for rare endocrine diseases and endocrine-related tumors, is on the Scientific Advisory Board of Homology Medicines, Inc., a public genetic medicines company, and Mitobridge, Inc., a biotechnology company acquired by Astellas Pharma Inc. in January 2018. Dr. Freeman previously served as Clinical Advisor to Relypsa, Inc., a biopharmaceutical company focused on protein therapeutics, and previously served as a director of Envoy Therapeutics, Inc., a biopharmaceutical company, until its acquisition by Takeda. Dr. Freeman holds a B.A. from Harvard College and a M.D. from the University of California, San Francisco.

Basic Compensation

Options Compensation